The Motley Fool
01 Jul 2026, 09:10 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Intuitive Surgical's Da Vinci 5 placements grew from 147 to 232 in the first quarter compared to the previous year. — Direct evidence of successful adoption of the newest high-margin product iteration, driving future recurring revenue.
+0.60The Da Vinci installed base grew by 12% year-over-year to 11,395 systems. — Expansion of the installed base increases the long-term floor for procedure-based consumables and service revenue.
+0.50Global Da Vinci procedures increased by 16% in the latest quarter. — Procedure growth is the primary driver of recurring revenue and validates the utility of the platform.
+0.50Medtronic's Hugo system is positioned as an additional choice rather than a direct superior replacement for the Da Vinci in urologic procedures. — Suggests a lack of disruptive competitive threat in the immediate term, preserving Intuitive's pricing power.
Continue reading
6 related stories
Search tags
Which stocks this story touches
The article highlights the company's strong moat, market dominance, and successful rollout of the Da Vinci 5 system.
Mentioned as a competitor, but the article suggests its new product does not meaningfully threaten the market leader.
Mentioned only in a generic navigation menu list of AI stocks without specific news or analysis.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
15h ago
